Novartis AG Net Worth 2010-2022 | NVS

Interactive chart of historical net worth (market cap) for Novartis AG (NVS) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Novartis AG net worth as of January 27, 2023 is $198.78B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $198.780B $51.626B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $441.560B 16.62
Eli Lilly (LLY) United States $330.671B 41.73
Novo Nordisk (NVO) Denmark $311.249B 40.81
Merck (MRK) United States $270.958B 13.95
AbbVie (ABBV) United States $260.674B 10.81
Pfizer (PFE) United States $248.389B 6.79